FDA Delays Decision On Biohaven's Troriluzole For Spinocerebellar Ataxia
15/5 05:27
(RTTNews) - Biohaven Ltd. (BHVN) announced that the Division of Neurology 1 within FDA's Office of Neuroscience informed the company that they have extended the PDUFA date for the troriluzole new drug application for the treatment of spinocerebellar ataxia (SCA) by three months t...